1/147
Looks like no tags are added yet.
prolong both pt and graft survival
What are the goals of transplantation?
more than 100,000
How many ppl are waiting on organ tranplants?
13
How many ppl die each day while awaiting organ transplants?
86%
What % of pts needs a transplant need a kidney?
up to 8 lives
How many lives can 1 donor save?
United Network for Organ Sharing (UNOS)
• Responsible for organ allocation in the US
• UNOS' computer system generates a ranked list of transplant candidates suitable to receive an organ when donor becomes available
Ranking factors vary by organ
• Medical urgency (heart/liver are prioritized if critically ill)
• Waiting time
• Organ size compatibility
• Distance between donor hospital and transplant center
• Biologic compatibility (blood type, tissue matching, etc.)
distance
Prioritization of candidates based on _________ from donor hospital
MELD (Model for End-Stage Liver Disease) Score
Organ Specific Scoring strongly influencing placement in the match for a liver
CAS (Composite Allocation Score)
Organ Specific Scoring strongly influencing placement in the match for a lung
Status 1-6 based on disease severity
Organ Specific Scoring strongly influencing placement in the match for a heart
KDPI (Kidney Donor Profile Index) and wait time
Organ Specific Scoring strongly influencing placement in the match for a kidney
US federal system for organ transplantation in the US
What is OPTN?
Organ Procurement and Transplantation Network
OPTN
OPTN
Coordinate organ donation and transplantation linking professionals, hospitals, and organizations to match donated organs with patients, increase organ availability, and ensure equitable allocation
transplant rejection
-Transplanting an organ/tissue from a donor into a recipient results in immune system activation leading to an attempt to destroy the transplanted organ
-often leads to graft damage and occasionally graft failures
Suppression of the immune system via lifelong medication
• Patient adherence is crucial
• Numerous medication side effects
How do we prevent rejection?
Allograft
-One individual to another
-Different genotype Same species (human to human)
Isograft
-genetically identical donor
-identical twin
autograft
-same patient
-one site to another (SCT)
xenograft
-between individuals
-different species (pig to human)
CMS (Center's for Medicare and Medicaid Services)
require a"pharmacology expert" typically a clinical transplant pharmacist to be part of the multidisciplinary team to meet accreditation standards and ensure patient safety and optimal medication management
Kidney indication for transplant
• ESRD due to hypertension and diabetes
• Glomerulonephritis
• Polycystic kidney disease
• Lupus
• Congenita
liver indications for transplant
• Metabolic dysfunction associated steatohepatitis (MASH)
• EtoH related cirrhosis
• Hepatitis B/C
• Hepatocellular carcinoma (HCC)
heart indications for transplant
• Cardiomyopathies
• Cardiovascular disease (CVD)
• Congenital
• Uncontrolled ventricular arrythmias
lung indications for transplant
• COPD
• Pulmonary fibrosis
• Cystic fibrosis
• Pulmonary hypertension
MHC
-allows T-cells to interact with antigen presenting cells (APCs)
-is expressed in all nucleated cells
-HLA in humans
HLA
encodes cell surface molecules which regulate the immune system
antibody formation
Exposure to non-self HLA leads to _________
immunologic risk
is defined by the presence of pre-formed antibodies to donor HLA
Panel Reactive Antibody (PRA)
amount of HLA antibody present in a potential recipient's serum
• Determined by testing the recipient serum to a panel of numerous types of HLA
• PRA >20% = sensitized; PRA >80% highly sensitized
Calculated PRA (cPRA)
represents the percentage of actual organ donors that express one or more unacceptable HLA antigens
• Includes HLA-A, -B, -DR, and -DQ
• Provides a meaningful estimate of transplantability
fewer
The higher the cPRA score the ______ compatible donors
10%
90% cPRA means possible match with _____ of the donor pool.
Crossmatching
pre-transplant immunologic screening test to detect donor specific antibodies (DSA) in the serum of the potential recipient
Positive crossmatch
recipient antibody activation to donor tissue
recipient has antibodies against donor tissue
Negative crossmatch
suitable donor → proceed to transplant
Donor Specific Antibody (DSA)
antibodies against donor antigens found within allograft vessels
• Preformed DSA or de novo DSA
Risk factors for de novo DSA
• High HLA mismatches (especially DQ mismatches)
• Inadequate immunosuppression and/or nonadherence
• Graft inflammation
DSA
High titers of _____ have been correlated with complement binding and more severe tissue injury
hyperacute reaction
What happens if a recipient who has type A blood receives a kidney from a type B donor?
ABO Incompatible Transplant
• Helps expand the donor pool
• Makes a historical barrier to transplant feasible
• Requires pre-transplant desensitization techniques
plasmapheresis (removal of antibodies) and immunosuppression (rituximab) which depletes b cells
What are the desensitization techniques used pre-transplantion in ABO incompatible pts?
A, O
Blood type A is compatible with:
B, O
Blood type B is compatible with:
A, B, AB, O
Blood type AB is compatible with:
O
Blood type O is compatible with:
increase risk of infection
-Lymphocyte depleting induction
-Donor derived infections
-Excess immune suppression
-Elderly
-Prior use of immunosuppressant
increase risk of rejection
-HLA mismatches
-Panel reactive antibody
-Pregnancy
-Blood transfusions
-Implantable devices
-Hemodialysis
-Prior transplant
minimize the risk of rejection but also balance the risk of infection
What is the goal of immunosuppression in SOT?
-induction immunosuppression
-maintenance immunosuppression
-treatment of rejection
What are the stages of immunosuppression in SOT?
Depleting induction
• Anti-thymocyte globulin (rATG) (Thymoglobulin®)
• Alemtuzumab (Campath®)
Non-depleting induction
• Basiliximab (Simulect®)
• Methylprednisolone
improves
Use of Induction Therapy ________ Graft Survival in Kidney Transplantation
Signal 1 of T cell activation
APC presents MHC Class II antigen to TH through the TCR-CD3 Complex
• Activates calcineurin pathway
• IL-2 is generated from the nucleus
signal 2 of t-cell activation
Co-stimulatory protein binding of CD80 and CD86 on theAPC to CD28 on the TH, initiating 3 signal transduction pathways
signal 3 of t cell activation
IL-2 is released and binds to IL-2 receptor on the T-cell, activating target of rapamycin necessary for cellular proliferation
activated proliferating T cell
Signal 1 + Signal 2 + Signal 3 equals:
Thymoglobulin
Available as Rabbit Antithymocyte Globulin (r-ATG; Thymoglobulin®)
• Used in SOT
Binds to various T cell markers leading to prolonged CD4 lymphocyte depletion
Rabbit Anti-Thymocyte Globulin(Thymoglobulin®, rATG) Mechanism of Action
V over 6 hours
• Give via central line; requires filter
• Risk of thrombophlebitis
• Can be given safely peripherally but not preferred
• Effects last 6-12 months
Admin of Rabbit Anti-Thymocyte Globulin (Thymoglobulin®, rATG):
Rabbit Anti-Thymocyte Globulin (Thymoglobulin®, rATG)
Adverse Effects
• Cytokine release syndrome and infusion site reactions
• Pre-medication is required
• acetaminophen/diphenhydramine/methylprednisolone 30 minutes prior to infusion
leukopenia and thrombocytopenia
What are the monitoring parameters of Rabbit Anti-Thymocyte Globulin (Thymoglobulin®, rATG)?
anaphylaxis (equine version- Atgam)
BBW for Rabbit Anti-Thymocyte Globulin (Thymoglobulin®, rATG):
Binds to CD52 on the surface of Tcells, B cells, monocytes, macrophages, NKcells, and a subpopulation of granulocytes
Alemtuzumab (Campath®) Mechanism of Action
IV; Peripheral orcentral
• Effects last 12+months
Admin of Alemtuzumab (Campath®):
AEs of Alemtuzumab (Campath®)
• Cytokine release syndrome
• Infusion site reactions
• Requires pre-medication
• Cytopenias
• Infections
Basiliximab (Simulect®)
-More commonly used if low risk for rejection or first line for liver transplantation
-decreased risk of infection vs depleting induction therapy
-effects lasts about 30 days
Chimeric (murine/human) monoclonal antibody that binds to and blocks the alpha chain of CD25 IL-2 receptor on activated T lymphocytes
Basiliximab (Simulect®) MOA
AEs of Basiliximab (Simulect®)
Non-specific (e.g., nausea, headache, hypertension)
Numerous; (i.e., decrease leukocyte accumulation, lymphocyte and complement function, cytokine release, etc.)
Methylprednisolone MOA
IV taper to oral; central or peripheral line
Methylprednisolone admin:
AEs of Methylprednisolone
• Hyperglycemia
• Peptic ulcers
• Leukocytosis
• Edema/weight gain
• Mood disturbances
• Insomnia
• Osteoporosis
Maintenance Immunosuppression
-pt specific factors are imp in determining this
-individualized based on the person and the transplant center
-no one size fits all approach
Calcineurin inhibitor + antimetabolite + steroid
Triple Maintenance Immunosuppression
Calcineurin Inhibitors
-Tacrolimus
-Cyclosporine
Capsule, granules for oral solution, injection
Tacrolimus (FK 506) formulations
Prograf®, Astagraf XL®(extended-release tacrolimus), Envarsus XR® (extended-release tacrolimus)
Tacrolimus brand names
Binds to FK binding protein -> complex binds to calcineurin -> blocks IL-2
Tacrolimus MOA
Individualized weight based dose to achieve goal trough levels
Tacrolimus dosing:
Prograf
All of the Tacrolimus formulations are QD except _______ is BID!
AEs of Tacrolimus
Hypomagnesemia, hypertension, hyperglycemia, neurotoxicity (headache, tremors, seizure, neuropathy), nephrotoxicity, new onset diabetes after transplant (NODAT), alopecia
1:4 or 1:5
Prograf IV to PO conversion:
2:1
Prograf PO to Sublingual conversion:
1:1
Astagraf to Prograf conversion:
1:0.8
Prograf to Envarsus XR
Astagraf to Envarsus XR
conversion is the same:
Increased risk of malignancy (lymphoma; skin cancer); increased risk of infection
BW with Tacrolimus:
Binds to cyclophilin -> complex binds to calcineurin -> blocks IL-2 production
Cyclosporine MOA
AEs of Cyclosporine
Hyperkalemia, hyperlipidemia, hyperglycemia, hypomagnesemia, gingival hyperplasia, hirsutism, neurotoxicity, hyperuricemia
Formulations of Cyclosporine
Capsule, oral solution, injection twice daily
Non-modified (Sandimmune®) vs. Modified (Neoral®/Gengraf®)
• Modified cyclosporine formulated for better absorption and bioavailability; microemulsion formula
• Not interchangeable
Increased risk of malignancy; increased risk of infection, nephrotoxicity (at anytrough level); hypertension
BW with Cyclosporine:
1:3
Cyclosporine IV to PO conversion:
Rifampin
Phenytoin
Carbamazepine
Phenobarbital
Isoniazid
St. Johns Wort
What are the CYP3A4 Inducers that decrease Calcineurin inhibitor drug levels:
Azole antifungals
Diltiazem
Verapamil
Erythromycin
Clarithromycin
Protease inhibitors
Grapefruit juice
Amiodarone
What are the CYP3A4 inhibitors that increase calcineurin inhibitor drug levels?
converted to active form mycophenolic acid; inhibits inosine monophosphate dehydrogenase which is responsible for de novo purine and DNA synthesis in T and B cells
Mycophenolate Mofetil(Cellcept®)Mycophenolic Acid (Myfortic®) MOA
formulations of Mycophenolate Mofetil(Cellcept®)Mycophenolic Acid (Myfortic®)
CellCept®- Tablet; capsule; suspension; injection; Myfortic® - delayed release tablet *Do not interchange without authorization*
250 mg CellCept= 180 mg Myfortic
Dosing conversion of Celll Cept to Myfortic
AEs of Mycophenolate Mofetil(Cellcept®)Mycophenolic Acid (Myfortic®)
Diarrhea, nausea, vomiting, leukopenia
pregnancy; mycophenolate REMS
CI with Mycophenolate Mofetil(Cellcept®) Mycophenolic Acid (Myfortic®):
Increased risk of malignancy (skin cancer; lymphoma); increased risk of infection, increased risk of congenital malformations and spontaneous abortions
BW of Mycophenolate Mofetil (Cellcept®) Mycophenolic Acid (Myfortic®):